Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CANTIL vs DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE)
Head-to-head clinical comparison of therapeutic indices and safety profiles.
CANTIL (mepenzolate bromide) is a quaternary ammonium anticholinergic agent that blocks muscarinic acetylcholine receptors, reducing gastrointestinal motility and gastric acid secretion.
Competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3) in the gastrointestinal tract, producing antispasmodic effects by reducing smooth muscle contractions.
Adjunctive therapy in peptic ulcer disease,Irritable bowel syndrome,Gastroenteritis,Diverticulitis,Ulcerative colitis
FDA-approved: irritable bowel syndrome (IBS) in patients with diarrhea or mixed bowel habits,Off-label: functional dyspepsia, biliary colic, urinary incontinence, hyperhidrosis
50 mg orally three times daily, may increase to 100 mg three times daily if needed
20 mg intramuscularly every 4-6 hours.
Terminal elimination half-life is approximately 10-12 hours; clinically, this supports twice-daily dosing in patients with normal renal function.
5-8 hours; may be prolonged in elderly or patients with hepatic impairment
Primarily metabolized by ester hydrolysis; excreted unchanged in bile and urine.
e GFR 30-59 m L/min: 50 mg twice daily; e GFR 15-29 m L/min: 50 mg once daily; e GFR <15 m L/min: not recommended
No specific adjustment required; use caution in severe impairment.
None.
CANTIL (mepenzolate bromide) is an anticholinergic quaternary ammonium compound. Limited human data; no evidence of teratogenicity in animal studies. In first trimester, theoretical risk of minor malformations due to anticholinergic effects; avoid unless clearly needed. Second and third trimesters: may cause fetal tachycardia, decreased GI motility, and potentially contribute to meconium ileus or neonatal anticholinergic syndrome if used near term. Weigh risk versus benefit.
Animal studies have not shown fetal harm; no adequate human studies in pregnancy. Risk cannot be ruled out. Avoid first trimester if possible.
CANTIL (mepenzolate bromide) is a quaternary ammonium anticholinergic used for functional gastrointestinal disorders. Avoid in patients with glaucoma, myasthenia gravis, or obstructive uropathy. May exacerbate GERD by reducing lower esophageal sphincter tone. Onset is rapid; duration 4-6 hours. Use with caution in elderly due to risk of anticholinergic side effects.
Dicyclomine hydrochloride is an anticholinergic agent used for irritable bowel syndrome (IBS). It can cause blurred vision, dry mouth, and urinary retention. Avoid in patients with glaucoma, myasthenia gravis, or obstructive uropathy. Use with caution in elderly due to fall risk.
No interactions on record
No interactions on record
CANTIL and DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE) are distinct pharmacological agents. CANTIL belongs to the Anticholinergic / Antispasmodic class and is primarily used for Adjunctive therapy in peptic ulcer diseaseIrritable bowel syndromeGastroenteritisDiverticulitisUlcerative colitis. DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE) belongs to the Anticholinergic class and is primarily used for FDA-approved: irritable bowel syndrome (IBS) in patients with diarrhea or mixed bowel habitsOff-label: functional dyspepsia, biliary colic, urinary incontinence, hyperhidrosis. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. CANTIL carries a safety status of Category C, whereas DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE) safety is classified as Category A/B. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Hepatic (major pathway): N-desmethylation via CYP3A4, minor pathways via CYP2D6.
Primarily renal excretion of unchanged drug and metabolites; approximately 60-70% eliminated renally, with about 30-40% excreted in feces via biliary elimination.
Renal (approximately 50-80% as unchanged drug and metabolites), biliary/fecal (minor, <10%)
Approximately 90-95% bound to plasma proteins, primarily albumin.
~90% bound to plasma proteins, primarily albumin
Vd approximately 1.2-1.5 L/kg, indicating extensive tissue distribution.
3.0-3.5 L/kg; indicates extensive tissue distribution
Oral bioavailability is approximately 60-70% due to first-pass metabolism.
Oral: approximately 67% (due to first-pass metabolism); Intramuscular: 100%
Child-Pugh A: no adjustment; Child-Pugh B: 50 mg twice daily; Child-Pugh C: not recommended
No specific adjustment required; use caution in severe impairment.
Safety and efficacy not established in pediatric patients; use not recommended
Not recommended for use in pediatric patients.
Start at 25 mg twice daily; titrate cautiously due to increased anticholinergic sensitivity and renal impairment risk
Initiate at lower dose (10 mg) due to increased sensitivity to anticholinergic effects.
No FDA boxed warning.
Heat prostration in hot environments due to decreased sweating; glaucoma; urinary retention; hyperthyroidism; coronary artery disease; congestive heart failure; cardiac arrhythmias; hiatal hernia; impaired renal or hepatic function; prostatic hypertrophy; obstructive uropathy.
Hypersensitivity to mepenzolate or any component of the formulation; glaucoma; obstructive uropathy (e.g., bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (e.g., achalasia, pyloroduodenal stenosis); paralytic ileus; intestinal atony; severe ulcerative colitis; myasthenia gravis; unstable cardiovascular status in acute hemorrhage; toxic megacolon complicating ulcerative colitis; acute angle-closure glaucoma.
Avoid high-fat meals as they may delay absorption. No specific food interactions; maintain adequate fluid intake to prevent constipation.
No specific food interactions. However, alcohol and central nervous system depressants may enhance sedative effects. Avoid excessive consumption of caffeine or acidic foods that may worsen GI symptoms.
Unknown if CANTIL is excreted in human milk. M/P ratio not available. Anticholinergic quaternary ammonium compounds have limited GI absorption and theoretical risk of anticholinergic effects in infant (dry mouth, constipation, tachycardia). Caution advised; use only if benefit outweighs risk. Monitor infant for anticholinergic symptoms.
Excreted in breast milk in small amounts; M/P ratio unknown. Use with caution in nursing mothers due to potential anticholinergic effects in infants.
No specific pharmacokinetic studies in pregnancy. Pregnancy-induced increased plasma volume and renal clearance may reduce drug concentrations, but quaternary ammonium compounds have limited absorption and variable distribution. No standard dose adjustments recommended; use lowest effective dose for shortest duration. Monitor clinical response and adjust based on tolerability.
No specific dose adjustments recommended; use lowest effective dose due to increased plasma volume and GFR pregnancy.
Take CANTIL 30-60 minutes before meals and at bedtime.,Avoid driving or operating machinery if you experience drowsiness or blurred vision.,Report severe constipation, difficulty urinating, or eye pain immediately.,Do not take with antacids; separate by at least 2 hours.,Limit alcohol consumption as it may increase sedation.
Take exactly as prescribed; do not exceed 40 mg per day in divided doses.,Do not take if you have glaucoma, severe constipation, or trouble urinating.,Avoid driving or operating heavy machinery if you experience blurred vision or dizziness.,Report any painful or difficult urination to your doctor immediately.,Swallow capsules whole; do not crush or chew.